Potassium%25252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte replacement medication used to treat or prevent hypokalemia. It is available in various oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia (serum potassium < 3.5 mEq/L). * Prevention of hypokalemia in patients at risk. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-100 mEq/day, divided into 2-5 doses. Higher doses may be used in severe cases under close monitoring. Maximum daily dose is generally not to exceed 200 mEq/day. * **Prevention of hypokalemia:** Typically 20-40 mEq/day, divided into 1-2 doses. * **Specific formulations:** Doses vary by formulation (e.g., tablets, liquid, extended-release capsules). Always refer to specific product labeling. Extended-release formulations usually require once or twice daily dosing. * **Intravenous (IV):** * **Treatment of hypokalemia:** * **Mild to moderate (< 3.5 mEq/L):** Typically 20-40 mEq added to a large volume IV fluid (e.g., 1 L of D5W or NS). Maximum infusion rate generally 10-20 mEq/hour. * **Severe or symptomatic (< 2.5 mEq/L):** Higher doses may be administered more rapidly (e.g., 20-40 mEq/hour) in a critical care setting with continuous cardiac monitoring. Maximum single dose often 40 mEq. Maximum total daily dose can be up to 200 mEq. * **Important:** IV potassium is a **high-alert medication**. Administer with extreme caution and continuous cardiac monitoring, especially for rapid infusions. Peripheral IV administration is limited to concentrations ≤ 40 mEq/L and infusion rates ≤ 10-20 mEq/hour to prevent phlebitis and pain. Central venous access is preferred for higher concentrations or faster rates. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** Doses vary widely based on age and severity, often calculated as 1-3 mEq/kg/day divided into doses. Maximum daily dose generally 100 mEq/day. * **Prevention of hypokalemia:** Doses typically range from 0.5-1 mEq/kg/day. * **Specific formulations:** Use pediatric-specific formulations or dilute adult liquid preparations to ensure accurate dosing. * **Intravenous (IV):** * **Treatment of hypokalemia:** Doses typically 0.5-1 mEq/kg per dose, added to IV fluids. Maximum infusion rate typically 0.3-0.5 mEq/kg/hour (maximum 20 mEq/hour) in neonates and children, but can be up to 1 mEq/kg/hour (maximum 40 mEq/hour) in older children and adolescents, especially with cardiac monitoring. * **Important:** Refer to institutional protocols and pediatric critical care guidelines for precise IV dosing and infusion rates. ## Dose Adjustments * **Renal Impairment:** Dose reduction is essential. Monitor potassium levels closely. Avoid potassium-containing medications and supplements if possible. In severe renal impairment, potassium supplementation may be contraindicated. * **Hepatic Impairment:** No specific dose adjustment, but monitor electrolytes. ## Contraindications * Hyperkalemia (serum potassium > 5.0 mEq/L). * Conditions leading to increased potassium levels (e.g., severe renal failure, untreated Addison's disease, extensive tissue destruction). * Known hypersensitivity to potassium chloride. * Gastrointestinal obstruction or delay in motility (for oral formulations). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain, gastric irritation, ulceration, bleeding, obstruction (especially with extended-release oral formulations). * **Cardiovascular:** ECG changes (peaked T waves, flattened P waves, prolonged QRS, loss of P waves, arrhythmias, cardiac arrest), hypotension. * **Neuromuscular:** Weakness, paresthesia, paralysis. * **Other:** Hyperkalemia. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors (e.g., lisinopril, enalapril) and Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan):** Increased risk of hyperkalemia. * **NSAIDs (e.g., ibuprofen, naproxen):** May reduce the effectiveness of potassium chloride and increase the risk of hyperkalemia. * **Cyclosporine, tacrolimus:** Increased risk of hyperkalemia. * **Digoxin:** Hyperkalemia can potentiate digoxin toxicity. Hypokalemia can increase the risk of digoxin toxicity. * **Sodium polystyrene sulfonate:** May bind to potassium chloride in the GI tract, reducing absorption. ## Monitoring * **Serum potassium levels:** Frequently monitor, especially during initiation of therapy, dose changes, or in patients with renal impairment or concurrent interacting medications. * **Renal function (BUN, creatinine):** Essential for dose adjustment. * **ECG:** Monitor for signs of hyperkalemia, especially with rapid IV infusions or in patients with pre-existing cardiac disease. * **Signs and symptoms of hypokalemia/hyperkalemia.** * **Fluid and electrolyte balance.** ## Clinical Pearls * Oral potassium chloride can cause significant gastrointestinal irritation. Administer with food or a large glass of water. Extended-release formulations should be swallowed whole and not crushed, chewed, or broken. * IV potassium is a high-alert medication. Double-check doses, concentrations, and infusion rates. Always use an infusion pump. * Rapid IV administration of potassium chloride can be fatal. Ensure adequate dilution and appropriate infusion rates. * In patients with severe hypokalemia (serum K < 2.5 mEq/L) or significant symptoms, IV administration is often necessary. * Correction of hypokalemia can be slow, especially with oral therapy. * Always consider the underlying cause of hypokalemia and address it concurrently. *** *Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional protocols before making clinical decisions. Dosing and safety information can change.*